ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$0.66 USD
+0.07 (12.68%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.66 0.00 (-0.17%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALXO 0.66 +0.07(12.68%)
Will ALXO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALXO
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ALXO
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 | ALXO Stock News
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
ALX Oncology Confirms Directors at Annual Meeting
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference | ALXO Stock News
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO)